vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and Syndax Pharmaceuticals Inc (SNDX). Click either name above to swap in a different company.
Syndax Pharmaceuticals Inc is the larger business by last-quarter revenue ($68.5M vs $57.3M, roughly 1.2× RHYTHM PHARMACEUTICALS, INC.). RHYTHM PHARMACEUTICALS, INC. runs the higher net margin — -83.0% vs -99.3%, a 16.3% gap on every dollar of revenue. On growth, Syndax Pharmaceuticals Inc posted the faster year-over-year revenue change (791.7% vs 36.9%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
Syndax Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies for patients with hard-to-treat cancers. Its pipeline includes targeted and immunotherapy candidates addressing unmet medical needs, primarily serving global oncology healthcare stakeholders and patient populations.
RYTM vs SNDX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $68.5M |
| Net Profit | $-47.5M | $-68.0M |
| Gross Margin | 91.6% | — |
| Operating Margin | -82.2% | -91.3% |
| Net Margin | -83.0% | -99.3% |
| Revenue YoY | 36.9% | 791.7% |
| Net Profit YoY | -9.6% | 27.8% |
| EPS (diluted) | $-0.73 | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.3M | $68.5M | ||
| Q3 25 | $51.3M | $45.9M | ||
| Q2 25 | $48.5M | $38.0M | ||
| Q1 25 | $32.7M | $20.0M | ||
| Q4 24 | $41.8M | — | ||
| Q3 24 | $33.3M | $12.5M | ||
| Q2 24 | $29.1M | — | ||
| Q1 24 | $26.0M | $0 |
| Q4 25 | $-47.5M | $-68.0M | ||
| Q3 25 | $-52.9M | $-60.7M | ||
| Q2 25 | $-46.6M | $-71.8M | ||
| Q1 25 | $-49.5M | $-84.8M | ||
| Q4 24 | $-43.3M | — | ||
| Q3 24 | $-43.6M | $-84.1M | ||
| Q2 24 | $-32.3M | — | ||
| Q1 24 | $-141.4M | $-72.4M |
| Q4 25 | 91.6% | — | ||
| Q3 25 | 89.3% | — | ||
| Q2 25 | 88.6% | — | ||
| Q1 25 | 88.8% | — | ||
| Q4 24 | 90.9% | — | ||
| Q3 24 | 88.5% | — | ||
| Q2 24 | 89.9% | — | ||
| Q1 24 | 89.2% | — |
| Q4 25 | -82.2% | -91.3% | ||
| Q3 25 | -102.6% | -125.2% | ||
| Q2 25 | -93.4% | -182.7% | ||
| Q1 25 | -143.7% | -417.9% | ||
| Q4 24 | -98.6% | — | ||
| Q3 24 | -132.0% | -716.6% | ||
| Q2 24 | -139.2% | — | ||
| Q1 24 | -538.7% | — |
| Q4 25 | -83.0% | -99.3% | ||
| Q3 25 | -103.1% | -132.4% | ||
| Q2 25 | -96.1% | -189.3% | ||
| Q1 25 | -151.4% | -423.3% | ||
| Q4 24 | -103.6% | — | ||
| Q3 24 | -131.2% | -673.0% | ||
| Q2 24 | -110.9% | — | ||
| Q1 24 | -544.4% | — |
| Q4 25 | $-0.73 | $-0.78 | ||
| Q3 25 | $-0.82 | $-0.70 | ||
| Q2 25 | $-0.75 | $-0.83 | ||
| Q1 25 | $-0.81 | $-0.98 | ||
| Q4 24 | $-0.71 | — | ||
| Q3 24 | $-0.73 | $-0.98 | ||
| Q2 24 | $-0.55 | — | ||
| Q1 24 | $-2.35 | $-0.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | $394.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.1M | $64.6M |
| Total Assets | $480.2M | $529.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.9M | $394.1M | ||
| Q3 25 | $416.1M | $436.0M | ||
| Q2 25 | $291.0M | $455.2M | ||
| Q1 25 | $314.5M | $512.2M | ||
| Q4 24 | $320.6M | — | ||
| Q3 24 | $298.4M | $389.6M | ||
| Q2 24 | $319.1M | — | ||
| Q1 24 | $201.2M | $434.6M |
| Q4 25 | $139.1M | $64.6M | ||
| Q3 25 | $148.8M | $115.4M | ||
| Q2 25 | $-11.9M | $157.4M | ||
| Q1 25 | $18.9M | $215.1M | ||
| Q4 24 | $21.7M | — | ||
| Q3 24 | $11.2M | $366.4M | ||
| Q2 24 | $39.3M | — | ||
| Q1 24 | $61.6M | $491.9M |
| Q4 25 | $480.2M | $529.7M | ||
| Q3 25 | $506.9M | $551.8M | ||
| Q2 25 | $372.7M | $596.1M | ||
| Q1 25 | $386.7M | $640.7M | ||
| Q4 24 | $392.3M | — | ||
| Q3 24 | $363.6M | $425.8M | ||
| Q2 24 | $381.8M | — | ||
| Q1 24 | $258.7M | $543.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $-69.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.4M | $-69.5M | ||
| Q3 25 | $-26.6M | $-70.5M | ||
| Q2 25 | $-23.3M | $-87.8M | ||
| Q1 25 | $-40.4M | $-95.2M | ||
| Q4 24 | $-18.8M | — | ||
| Q3 24 | $-25.2M | $-62.3M | ||
| Q2 24 | $-29.1M | — | ||
| Q1 24 | $-40.7M | $-83.5M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
